Division of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, London, United Kingdom.
Institute of Biochemistry and Biotechnology, Martin Luther University Halle-Wittenberg, Halle, Germany; and.
Am J Respir Crit Care Med. 2021 Aug 15;204(4):421-430. doi: 10.1164/rccm.202009-3545OC.
Mechanical ventilation is a mainstay of intensive care but contributes to the mortality of patients through ventilator-induced lung injury. eCypA (extracellular CypA [cyclophilin A]) is an emerging inflammatory mediator and metalloproteinase inducer, and the gene responsible for its expression has recently been linked to coronavirus disease (COVID-19). To explore the involvement of eCypA in the pathophysiology of ventilator-induced lung injury. Mice were ventilated with a low or high Vt for up to 3 hours, with or without blockade of eCypA signaling, and lung injury and inflammation were evaluated. Human primary alveolar epithelial cells were exposed to stretching to explore the cellular source of eCypA, and CypA concentrations were measured in BAL fluid from patients with acute respiratory distress syndrome to evaluate the clinical relevance. High-Vt ventilation in mice provoked a rapid increase in soluble CypA concentration in the alveolar space but not in plasma. ventilation and stretching experiments indicated the alveolar epithelium as the likely major source. blockade of eCypA signaling substantially attenuated physiological dysfunction, macrophage activation, and MMPs (matrix metalloproteinases). Finally, we found that patients with acute respiratory distress syndrome showed markedly elevated concentrations of eCypA within BAL fluid. CypA is upregulated within the lungs of injuriously ventilated mice (and critically ill patients), where it plays a significant role in lung injury. eCypA represents an exciting novel target for pharmacological intervention.
机械通气是重症监护的主要手段,但通过呼吸机引起的肺损伤导致患者死亡率增加。eCypA(细胞外 CypA[亲环素 A])是一种新兴的炎症介质和金属蛋白酶诱导剂,其表达的基因最近与冠状病毒病(COVID-19)有关。为了探讨 eCypA 在呼吸机引起的肺损伤中的作用机制。用低或高 Vt 对小鼠进行通气长达 3 小时,并用或不用 eCypA 信号阻断,评估肺损伤和炎症。将人原代肺泡上皮细胞暴露于拉伸,以探索 eCypA 的细胞来源,并测量急性呼吸窘迫综合征患者 BAL 液中的 CypA 浓度以评估临床相关性。在小鼠中进行高 Vt 通气会迅速增加肺泡空间中可溶性 CypA 的浓度,但不会增加血浆中的浓度。通气和拉伸实验表明肺泡上皮细胞可能是主要来源。阻断 eCypA 信号可显著减轻生理功能障碍、巨噬细胞激活和 MMPs(基质金属蛋白酶)。最后,我们发现急性呼吸窘迫综合征患者的 BAL 液中 eCypA 浓度明显升高。在损伤性通气的小鼠(和重症患者)的肺部中,CypA 上调,在肺损伤中发挥重要作用。eCypA 代表了一种令人兴奋的新型药物干预靶点。